Autonomous Therapeutics

Executive Summary

Autonomous Therapeutics is a private biotechnology company pioneering next-generation RNA therapeutics using its proprietary Encrypted RNA™ platform. The platform enables the creation of target-activated, variant-agnostic nucleic acid medicines, which are designed to selectively modulate disease-associated RNA targets while minimizing off-target effects. The company’s pipeline includes programs in infectious diseases, such as influenza, and oncology, including colon cancer. By leveraging a novel mechanism that allows therapeutic activation only in the presence of specific disease-associated RNA sequences, Autonomous aims to improve potency and safety compared to conventional RNA therapies. The platform’s variant-agnostic nature also positions it to address rapidly mutating pathogens and heterogeneous tumors. As a privately held, early-stage company, Autonomous Therapeutics has not disclosed significant funding or clinical milestones, but its unique approach has the potential to address high unmet needs across multiple therapeutic areas.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round60% success
• Q2 2027Preclinical Proof-of-Concept Data Release for Influenza Program55% success
• H2 2027Strategic Partnership or Licensing Deal for Oncology Pipeline40% success